Carboplatin addition to standard chemotherapy improves event-free survival in early-stage triple-negative breast cancer
Adding carboplatin improves survival for triple-negative breast cancer
This phase III trial evaluated the addition of carboplatin to a doxorubicin and cyclophosphamide regimen followed by a taxane in patients wi…
Adding carboplatin to standard chemotherapy improves event-free survival for women with early-stage triple-negative breast cancer.
Pembrolizumab reduces death risk by 34% in early-stage triple-negative breast cancer patients
New Treatment Options Improve Survival for Patients with Triple Negative Breast Cancer
This meta-analysis of 3133 patients evaluates the efficacy of pembrolizumab and capecitabine in early-stage triple-negative breast cancer. T…
Doctors are finding that combining specific drugs can significantly improve survival rates and keep cancer from returning in early-stage pat…
Sacituzumab tirumotecan shows manageable safety profile in metastatic triple-negative breast cancer
Trial shows manageable safety for triple-negative breast cancer treatment
This randomized controlled trial post-hoc exploratory analysis of 262 patients with metastatic triple-negative breast cancer evaluated the s…
A new analysis shows that patients with triple-negative breast cancer can manage common side effects during treatment.
Immune Checkpoint Inhibitors Combined With Chemotherapy Improve Pathological Complete Response in TNBC
Immunotherapy Combined With Chemotherapy Shows Higher Response Rates in TNBC
Combining immune checkpoint inhibitors with chemotherapy significantly improves pathological complete response rates in patients with triple…
Adding immunotherapy to chemotherapy may improve response rates for patients with early-stage or high-risk triple-negative breast cancer.
Tumor necrosis-related fever may occur during neoadjuvant chemoimmunotherapy for metaplastic breast carcinoma
Case Report Shows Tumor Necrosis Fever in Breast Cancer Treatment
This case report describes a patient with triple-negative breast cancer receiving neoadjuvant chemoimmunotherapy who experienced a tumor nec…
A single case study highlights how a persistent fever during chemotherapy may be caused by tumor necrosis rather than an infection.
RPN1 overexpression promotes immune evasion and treatment resistance in multiple malignancies including hepatocellular carcinoma
RPN1 Protein Linked to Worse Outcomes in Several Cancers
This systematic review examines the role of RPN1 in glioma, hepatocellular carcinoma, sarcoma, and triple-negative breast cancer. The author…
High levels of the RPN1 protein are linked to aggressive cancer features and help tumors hide from the body's immune system.
ICIs Boost pCR in Early Triple-Negative Breast Cancer
Immune drugs combined with chemotherapy improve results for triple-negative breast cancer
Adding immune checkpoint inhibitors to chemotherapy improves pathological complete response in early triple-negative breast cancer, with PD-…
Adding immune checkpoint inhibitors to chemotherapy significantly increases the chance of clearing cancer cells in triple-negative breast ca…
Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC
New data shows specific drug combinations improve triple-negative breast cancer outcomes
This network meta-analysis of 7,683 patients with early-stage triple-negative breast cancer (TNBC) evaluated various neoadjuvant treatment r…
New data shows that adding specific drugs like pembrolizumab or bevacizumab to standard chemotherapy can improve response rates for early-st…
Targeted therapy plus chemotherapy improves objective response and disease control rates in advanced TNBC
Targeted therapy plus chemotherapy improves response in triple-negative breast cancer
This systematic review and meta-analysis of 523 patients found that adding targeted therapy to chemotherapy for advanced triple-negative bre…
Adding targeted therapy to chemotherapy may improve how tumors respond in patients with advanced triple-negative breast cancer.
Adjuvant CDK4/6 inhibitors improve invasive Disease-Free Survival regardless of patient menopausal status
CDK4/6 inhibitors show consistent results for both pre and postmenopausal women
This meta-analysis of 17,748 patients with HR+ and HER2-negative early breast cancer found that adjuvant CDK4/6 inhibitors improved invasive…
New data suggests that a specific type of breast cancer treatment works effectively regardless of whether a patient has reached menopause.
Neoadjuvant immune checkpoint inhibitors plus chemotherapy increase pathological complete response in early-stage triple-negative breast cancer
Immune checkpoint inhibitors improve response in triple-negative breast cancer
This meta-analysis of 3,377 patients found that neoadjuvant immune checkpoint inhibitors combined with chemotherapy significantly increased …
Adding immune checkpoint inhibitors to chemotherapy helps more patients with early-stage triple-negative breast cancer achieve a complete re…
Chemokine networks regulate triple-negative breast cancer tumor microenvironment but clinical translation remains limited
Chemokine Targets Show Promise in Lab but Face Clinical Hurdles
This systematic review examines the role of chemokine networks and targeted interventions in the triple-negative breast cancer immune microe…
New research highlights the role of chemokine networks in breast cancer, showing strong results in labs despite challenges in current clinic…
Research across Cancer
Related studies from across the Cancer family.
Enzalutamide added to ADT improves survival in APIC-negative metastatic hormone-sensitive prostate cancer
Trial shows enzalutamide helps specific patients with prostate cancer
This randomized controlled trial analyzed 492 patients with metastatic hormone-sensitive prostate cancer to evaluate the impact of the APIC …
A new analysis shows that a specific biomarker can help doctors identify which prostate cancer patients may benefit most from enzalutamide t…
Trastuzumab Deruxtecan Management of HER2 Positive Metastatic Breast Cancer with Visceral Crisis
Newer drug shows promise for advanced breast cancer and liver issues
A case report highlights the efficacy of trastuzumab deruxtecan in managing visceral crisis in HER2-positive metastatic breast cancer.
A new treatment approach may help patients with advanced breast cancer who are facing a sudden, serious crisis in their liver function.
Rezvilutamide plus ADT with efavirenz-based ART yields PSA decline in one HIV-positive mHSPC patient
Rezvilutamide Shows Promise for Prostate Cancer in HIV Patients
This is a single-patient case report describing rezvilutamide plus androgen deprivation therapy in an HIV-positive patient with high-volume …
A single patient with both HIV and advanced prostate cancer showed significant improvement after starting a specific combination of treatmen…
Evaluating AI and Manual Stromal Immune Cell Quantification in HER2 Positive Breast Cancer
AI tools help predict outcomes for HER2-positive breast cancer
This Phase 3 analysis evaluates how manual, digital, and AI-based sTIL quantification impact prognostic and predictive outcomes in HER2+ bre…
New analysis shows that AI and manual counts of immune cells can help predict how well patients with HER2-positive breast cancer respond to …
Meridian Sinew Tuina significantly reduces upper limb circumference and pain in breast cancer-related lymphedema
Meridian Sinew Tuina May Help Manage Breast Cancer Lymphedema
This meta-analysis evaluated the impact of Meridian Sinew Tuina on patients with breast cancer-related lymphedema. The analysis found signif…
A specialized deep tissue massage technique called Meridian Sinew Tuina shows promise in reducing swelling and pain for those with breast ca…
Docetaxel and PARPi additions to ARPI and ADT improve progression-free survival in mHSPC
New data shows potential benefits for advanced prostate cancer patients
This network meta-analysis of 18,689 patients with metastatic hormone-sensitive prostate cancer (mHSPC) evaluated first-line systemic combin…
New data suggests that adding specific drugs to standard hormone therapy may help slow the growth of advanced prostate cancer.
Lead-in ADT reduces grade ≥3 neutropenia incidence in metastatic hormone-sensitive prostate cancer patients
Lead-in therapy may reduce severe low white blood cell counts
This post hoc analysis of a phase 3 trial and real-world validation study evaluated lead-in androgen-deprivation therapy (ADT) for patients …
A new look at clinical data suggests that a lead-in hormone treatment can help prevent serious low white blood cell counts in prostate cance…
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Lymphovenous anastomosis improves quality of life in breast cancer-related lymphedema
Lymphedema surgery improves quality of life in breast cancer survivors
This meta-analysis of observational studies found that therapeutic lymphovenous anastomosis (LVA) significantly improves quality of life in …
A new analysis finds that lymphovenous anastomosis significantly boosts quality of life for breast cancer survivors with lymphedema, especia…
Weight reduction ranked highest for limb volume, while VR-based training ranked highest for pain in breast cancer-related lymphedema
Weight loss and virtual reality rank highest for breast cancer swelling and pain relief
This network meta-analysis of 754 patients evaluated non-pharmacological therapies for breast cancer-related lymphedema. Weight reduction ra…
Weight loss and virtual reality training ranked best for reducing arm swelling and pain in breast cancer patients, though other therapies al…
Questions about Hormone Receptor-Positive Breast Cancer
Is trastuzumab deruxtecan better than chemotherapy for HR-positive breast cancer?
Yes, trastuzumab deruxtecan improves progression-free survival compared to chemotherapy in HR-positive, HER2-low breast cancer, but overall survival data are not yet mature.
Full answer →Does datopotamab deruxtecan improve survival for Hormone Receptor-Positive Breast Cancer?
Datopotamab deruxtecan did not improve overall survival compared to chemotherapy in metastatic HR-positive breast cancer, despite improving progression-free survival.
Full answer →All Hormone Receptor-Positive Breast Cancer Articles
- Carboplatin addition to standard chemotherapy improves event-free survival in early-stage triple-negative breast cancer
- Pembrolizumab reduces death risk by 34% in early-stage triple-negative breast cancer patients
- Sacituzumab tirumotecan shows manageable safety profile in metastatic triple-negative breast cancer
- Immune Checkpoint Inhibitors Combined With Chemotherapy Improve Pathological Complete Response in TNBC
- Tumor necrosis-related fever may occur during neoadjuvant chemoimmunotherapy for metaplastic breast carcinoma
- RPN1 overexpression promotes immune evasion and treatment resistance in multiple malignancies including hepatocellular carcinoma
- ICIs Boost pCR in Early Triple-Negative Breast Cancer
- Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC
- Targeted therapy plus chemotherapy improves objective response and disease control rates in advanced TNBC
- Adjuvant CDK4/6 inhibitors improve invasive Disease-Free Survival regardless of patient menopausal status
- Neoadjuvant immune checkpoint inhibitors plus chemotherapy increase pathological complete response in early-stage triple-negative breast cancer
- Chemokine networks regulate triple-negative breast cancer tumor microenvironment but clinical translation remains limited
- Datopotamab deruxtecan improves progression-free survival to 10.8 months versus 5.6 months in TNBC
- Adenomatoid tumor should be considered in the differential diagnosis for testicular lesions in patients with cryptorchidism
- Immune checkpoint inhibitors plus chemotherapy improve overall survival in advanced triple-negative breast cancer
- Multimodal fusion and radiogenomic frameworks show promise for capturing heterogeneity in triple-negative breast cancer
- Small intestinal metastasis from triple-negative breast cancer can mimic lymphoma on imaging
- Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
- Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
- Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
- Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
- Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
- Gut microbiome factors and dietary modulation may optimize triple-negative breast cancer management
- Docetaxel chemotherapy is highly suspect for causing acute myocardial infarction in a low-risk triple-negative breast cancer patient
- Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer
- Systematic review and meta-analysis on NY-ESO-1 expression in triple-negative breast cancer
- Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
- Neoadjuvant ICI plus chemotherapy improves event-free survival in early-stage TNBC
- Radiofrequency ablation followed by radiation therapy shows noninferior 5-year recurrence-free survival compared to partial mastectomy in early stage breast cancer
- CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
- Capivasertib-paclitaxel fails to improve overall survival in metastatic TNBC
- Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
- AI-mediated ultrasonic radiomics shows potential for triple-negative breast cancer diagnosis and prognosis
- Review of immunotherapy innovations for triple-negative breast cancer survival
- Gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival versus fulvestrant monotherapy in advanced breast cancer
- Meta-analysis finds oral SERDs improve PFS over standard ET in HR+ HER2- ABC
- Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients
- Talazoparib monotherapy in neoadjuvant triple-negative breast cancer reveals BRN2-driven resistance mechanisms
- Adherence to 2021 ABS imaging recommendations in 148 male breast referrals at a UK hospital
- Sequential paclitaxel-palbociclib showed no difference in ORR versus reverse sequence in ER+/HER2- breast cancer
- Meta-analysis finds immunotherapy plus chemotherapy improves outcomes in triple-negative breast cancer
- Pyroptosis-related gene signature predicts prognosis in triple-negative breast cancer patients
- Neoadjuvant chemotherapy plus sintilimab improved response rates versus chemotherapy alone in 61 patients with triple-negative breast cancer
- Network meta-analysis of adjuvant chemotherapy regimens for early-stage breast cancer identifies optimal dosing sequences and safety profiles
- Atezolizumab plus chemotherapy improved progression-free survival and patient-reported quality of life in metastatic triple-negative breast cancer
- Phase Ib trial: Mam-A DNA vaccine plus endocrine therapy induces T cells in ER+ breast cancer
- PSMA PET/CT shows uptake in half of metastatic triple-negative breast cancer patients
- Population study links PALB2 variants to increased cancer risk and mortality in two large cohorts
- DIBH reduces radiation dose to heart and lungs in left-sided breast cancer VMAT
- Single-fraction stereotactic partial breast irradiation shows promising early control in early-stage breast cancer
- Adjusted Breast Cancer Index model identifies minimal-risk groups in premenopausal HR+ node-negative breast cancer